A Phase I Double-Blind, Randomized, Placebo-Controlled Study of the Safety, Tolerability and Immunogenicity of ACI-35 in Patients with Mild to Moderate Alzheimer's Disease

Trial Profile

A Phase I Double-Blind, Randomized, Placebo-Controlled Study of the Safety, Tolerability and Immunogenicity of ACI-35 in Patients with Mild to Moderate Alzheimer's Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs ACI 35 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors AC Immune
  • Most Recent Events

    • 03 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 17 Mar 2017 According to an AC Immune media release, further results are expected in secon half of 2017.
    • 17 Mar 2017 According to an AC Immune media release, till date safety and tolerability is considered satisfactory as assessed by the Data Safety Monitoring Board.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top